title: Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy.
authors.affiliation: Department of Neurosciences, UCSD Moores Cancer Center, La Jolla, California (D.E.P.); Neuro Oncology Program, David Geffen School of Medicine at UCLA., Los Angeles, California (A.L.).
authors.forename: David E
authors.initials: DE
authors.lastname: Piccioni
authors.affiliation: Department of Neurosciences, UCSD Moores Cancer Center, La Jolla, California (D.E.P.); Neuro Oncology Program, David Geffen School of Medicine at UCLA., Los Angeles, California (A.L.).
authors.forename: Albert
authors.initials: A
authors.lastname: Lai
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy*; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized